For the same degree of blood glucose reduction, metformin treatment is associated with a lower risk of hypoglycaemia than with insulin secretagogues and insulin treatment in patients with type-2 diabetes [7], [8]. The gene discussed is INS; the disease is type 2 diabetes mellitus.